R13 (drug)

In this article, we will explore the impact of R13 (drug) in various areas of contemporary society. R13 (drug) has been the subject of study and controversy for decades, and its influence ranges from popular culture to world politics. Through the analysis of R13 (drug), we will be able to better understand how it has shaped the way we live, think, and relate to the world around us. From its origins to its future projection, R13 (drug) continues to be a topic of debate and reflection, and this article aims to examine the different perspectives that exist around this phenomenon.

R13
Clinical data
Other names4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate)
Routes of
administration		By mouth[1]
Pharmacokinetic data
MetabolitesTropoflavin[1]
Identifiers
  • N-methylcarbamate
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC19H16N2O6
Molar mass368.345 g·mol−1
3D model (JSmol)
  • CNC(=O)OC1=C(C2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)OC(=O)NC
  • InChI=1S/C19H16N2O6/c1-20-18(23)26-14-9-8-12-13(22)10-15(11-6-4-3-5-7-11)25-16(12)17(14)27-19(24)21-2/h3-10H,1-2H3,(H,20,23)(H,21,24)
  • Key:NWWRHMSYZTWUBD-UHFFFAOYSA-N

R13 is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB) – the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF) – which is under development for the potential treatment of Alzheimer's disease.[1][2] It is a structural modification and prodrug of tropoflavin (7,8-DHF) with improved potency and pharmacokinetics, namely oral bioavailability and duration.[1] The compound is a replacement for the earlier tropoflavin prodrug R7 and has similar properties to it.[1][3] It was developed because while R7 displayed a good drug profile in animal studies, it showed almost no conversion into tropoflavin in human liver microsomes.[1] In contrast to R7, R13 is readily hydrolyzed into tropoflavin in human liver microsomes.[1]

See also

References

  1. ^ a b c d e f g Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y, Ye K (January 2018). "The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease". Proc. Natl. Acad. Sci. U.S.A. 115 (3): 578–583. Bibcode:2018PNAS..115..578C. doi:10.1073/pnas.1718683115. PMC 5777001. PMID 29295929.
  2. ^ US application 20150274692, Keqiang Ye, "7,8-Dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto", published 2015-10-01, assigned to Emory University 
  3. ^ Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Transl Neurodegener. 5: 2. doi:10.1186/s40035-015-0048-7. PMC 4702337. PMID 26740873.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.